RESUMEN
Congenital melanocytic nevus (CMN) syndrome represents a mosaic RASopathy, typically caused by postzygotic NRAS codon 61 mutations, which originate in ectodermal precursor cells and result in melanocyte deposits in the skin and central nervous system (CNS). Affected patients are prone to develop uniformly fatal melanomas in the skin and CNS. Here, we report the case of a 2.7-year-old male with CMN syndrome, diffuse leptomeningeal melanosis and CNS melanoma, who underwent experimental therapy with the DNA methyltransferase inhibitor azacitidine in combination with the mitogen-activated protein kinase (MEK) inhibitor trametinib with exceptional clinical and radiological response. Response to combination therapy appeared to be more durable than the treatment response observed in several other severely affected patients treated with trametinib for late-stage disease. Correspondingly, concomitant exposure to trametinib and azacitidine prevented development of trametinib resistance in NRAS-mutated human melanoma cells in vitro. Also, azacitidine was shown to inhibit growth and mitogen-activated protein kinase 1/2 (ERK1/2) phosphorylation of melanoma cells and act synergistically with trametinib to inhibit the growth of trametinib-resistant melanoma cells. These observations suggest that azacitidine enhances trametinib monotherapy and may represent a promising candidate drug for combination therapies to enhance the efficacy of MEK inhibitors in RAS-driven diseases.
Asunto(s)
Melanoma , Neoplasias Meníngeas , Neoplasias Cutáneas , Azacitidina/farmacología , Azacitidina/uso terapéutico , Preescolar , GTP Fosfohidrolasas/genética , Humanos , Masculino , Melanoma/tratamiento farmacológico , Melanoma/genética , Proteínas de la Membrana/genética , Neoplasias Meníngeas/tratamiento farmacológico , Quinasas de Proteína Quinasa Activadas por Mitógenos/genética , Quinasas de Proteína Quinasa Activadas por Mitógenos/uso terapéutico , Mutación , Nevo Pigmentado , Inhibidores de Proteínas Quinasas/uso terapéutico , Piridonas/farmacología , Piridonas/uso terapéutico , Pirimidinonas/farmacología , Pirimidinonas/uso terapéutico , Neoplasias Cutáneas/tratamiento farmacológicoRESUMEN
In recent years, our knowledge of congenital melanocytic nevi (CMN) has greatly expanded. This has led to a paradigm shift. The present article represents a commentary by an interdisciplinary group of physicians from German-speaking countries with extensive experience in long-term care and surgical treatment of children and adults with CMN (CMN surgery network, "Netzwerk Nävuschirurgie", NNC). The authors address aspects such as the indication for treatment as well as treatment planning and implementation under these new premises. Adequate counseling of parents on conservative and/or surgical management requires an interdisciplinary exchange among physicians and individualized planning of the intervention, which frequently involves a multi-stage procedure. Today, the long-term aesthetic outcome is at the center of any therapeutic endeavor, whereas melanoma prevention plays only a minor role. The premise of "removal at any cost" no longer holds. Potential treatment-related adverse effects (hospitalization, wound healing disorders, and others) must be carefully weighed against the prospects of a beneficial outcome. In this context, the use of dermabrasion in particular must be critically evaluated. At a meeting of the NNC in September 2018, its members agreed on a consensus-based position on dermabrasion, stating that the procedure frequently leads to impaired wound healing and cosmetically unfavorable or hypertrophic scarring. Moreover, dermabrasion is considered to be commonly associated with considerable repigmentation that usually occurs a number of years after the procedure. In addition, the NNC members saw no benefit in terms of melanoma prevention. In the future, physicians should therefore thoroughly caution about the potential risks and often limited cosmetic benefits of dermabrasion.
Asunto(s)
Cuidados a Largo Plazo/métodos , Nevo Pigmentado/congénito , Nevo Pigmentado/cirugía , Grupo de Atención al Paciente/normas , Neoplasias Cutáneas/patología , Preescolar , Cicatriz Hipertrófica/patología , Consejo/métodos , Dermabrasión/efectos adversos , Estética , Estudios de Seguimiento , Humanos , Melanoma/prevención & control , Nevo Pigmentado/clasificación , Padres/educación , Complicaciones Posoperatorias/epidemiología , Cicatrización de Heridas/fisiologíaRESUMEN
Giant congenital melanocytic nevi may be symptomatically isolated or syndromic. Associations with capillary malformations are exceptional, and development of epidermal cysts has not been described. A 71-year-old patient with a giant congenital melanocytic nevus (CMN) of the lower back, buttocks, and thighs was asymptomatic except for unexpected hemorrhage during partial surgical excision years before. Blunt trauma at age 64 initiated recurrent, severe pain under the nevus; multiple large epidermal cysts then developed within it. Imaging and biopsy showed a large, non-pulsatile venous malformation intermingled with the deep nevus. A low-abundance, heterozygous BRAF c.1799T>A (p.V600E) mutation was present in both gluteal and occipital congenital nevi; additional mutations in NRAS, GNAQ, GNA11, HRAS, or PIK3CA were undetectable. This is the first demonstration of a recurrent BRAF mutation in multiple large congenital nevi from the same individual, confirming that this malformation can have multiple genetic origins. Early constitutive activation of BRAF can therefore cause unusual associations of giant nevi with vascular malformations, indicating that both pigment and endothelial cell physiology may be affected by mosaic RASopathies.
Asunto(s)
Quiste Epidérmico , Mutación , Nevo Pigmentado , Proteínas Proto-Oncogénicas B-raf/genética , Malformaciones Vasculares , Anciano , Quiste Epidérmico/congénito , Quiste Epidérmico/enzimología , Quiste Epidérmico/patología , Quiste Epidérmico/cirugía , Humanos , Masculino , Nevo Pigmentado/congénito , Nevo Pigmentado/enzimología , Nevo Pigmentado/cirugía , Malformaciones Vasculares/enzimología , Malformaciones Vasculares/genética , Malformaciones Vasculares/patologíaRESUMEN
HINTERGRUND: Kongenitale melanozytäre Nävi (KMN) bedeuten für Patienten und Familien eine psychologische Belastung und bergen zudem medizinische Risiken. Das 2005 gegründete deutschsprachige KMN-Register wurde nun einer Zwischenauswertung bezüglich des Krankheitsverlaufes, der medizinischen Versorgung und der Lebensqualität unterzogen. PATIENTEN UND METHODIK: 100 Patienten, die sich in den Jahren 2005 bis 2012 mit einem Erstmeldebogen registriert hatten, wurde im Rahmen einer prospektiven Kohortenstudie Anfang 2013 ein Folgemeldebogen zugesandt. Außerdem wurden mithilfe standardisierter Fragebögen Daten zu Lebensqualität (dermatology life quality index, DLQI) und Stigmatisierungserfahrungen (perceived stigmatization questionnaire, PSQ; social comfort questionnaire, SCQ) erhoben. ERGEBNISSE: 83 % der Patienten oder deren Eltern antworteten (Altersdurchschnitt 11,2 Jahre, Median 6 Jahre; mittleres Follow-up 4,4 Jahre). Im Gesamtkollektiv wurden vier Melanome diagnostiziert, davon zwei zerebrale Melanome im Kindesalter, ein kutanes Melanom im Erwachsenenalter und eines, das sich als proliferierender Knoten erwies. Bei vier Kindern wurde eine neurokutane Melanozytose festgestellt, drei davon mit neurologischer Symptomatik. Chirurgisch behandelt wurden 88 % (73/83). Achtundsiebzig Prozent der Befragten berichteten eine geringe oder keine Beeinträchtigung der Lebensqualität. Die wahrgenommene Stigmatisierung beziehungsweise Beeinträchtigung des sozialen Wohlbefindens war generell ebenfalls gering. SCHLUSSFOLGERUNGEN: Die Ergebnisse geben einen Überblick über die Situation von Patienten mit KMN in Deutschland, Österreich und der Schweiz. Ein Melanom entwickelte sich in 3 %, eine ZNS-Beteiligung bestand in 4 % der Fälle.
RESUMEN
BACKGROUND: Congenital melanocytic nevi (CMN) are associated with mental stress as well as medical risks for those affected. The German CMN registry was initiated in 2005. Herein, we present results from an interim analysis focusing on disease course, treatment modalities, and quality of life. PATIENTS AND METHODS: One hundred patients enrolled in the registry between 2005 and 2012 were included in this prospective cohort study, and asked to participate in a follow-up survey. In addition, standardized questionnaires were used to collect data on quality of life (dermatology life quality index, DLQI) and perceived stigmatization (perceived stigmatization questionnaire, PSQ; social comfort questionnaire, SCQ). RESULTS: Eighty-three percent of patients (or their parents) provided answers to the survey questions (mean patient age: 11.2 years, median: 6 years; mean follow-up: 4.4 years). Overall, four individuals were diagnosed with melanoma, including two pediatric cases with CNS melanoma, one adult with cutaneous melanoma, and one case which later turned out to be a proliferative nodule. Four children were diagnosed with neurocutaneous melanocytosis, three of whom exhibited neurological symptoms. Eighty-eight percent (73/83) of patients underwent surgery. Seventy-eight percent reported no or only minor impact of the CMN on quality of life. In general, perceived stigmatization and impairment of social well-being were also low. CONCLUSIONS: Our results provide an overview of the situation of CMN patients in Germany, Austria, and Switzerland. Three percent of patients developed melanoma; 4 % showed CNS involvement.
Asunto(s)
Procedimientos Quirúrgicos Dermatologicos/estadística & datos numéricos , Enfermedades del Sistema Nervioso/psicología , Nevo Pigmentado/psicología , Nevo Pigmentado/terapia , Calidad de Vida/psicología , Sistema de Registros , Neoplasias Cutáneas/psicología , Neoplasias Cutáneas/terapia , Estereotipo , Adolescente , Adulto , Distribución por Edad , Austria/epidemiología , Niño , Preescolar , Estudios de Cohortes , Comorbilidad , Procedimientos Quirúrgicos Dermatologicos/psicología , Femenino , Alemania/epidemiología , Encuestas de Atención de la Salud , Humanos , Estudios Longitudinales , Masculino , Enfermedades del Sistema Nervioso/epidemiología , Nevo Pigmentado/epidemiología , Prevalencia , Factores de Riesgo , Distribución por Sexo , Neoplasias Cutáneas/epidemiología , Suiza/epidemiología , Resultado del Tratamiento , Adulto JovenRESUMEN
A new consensus-based classification of congenital melanocytic nevi (CMN) has recently been proposed. It includes categories for projected adult size (PAS) and location, satellite nevi counts, and morphologic characteristics (color heterogeneity, rugosity, nodularity, and hypertrichosis). The objective of the current study was to test the applicability of the new categorization scheme and to correlate classification outcome with the patient's history of melanoma and neurocutaneous melanocytosis (NCM). Children and adults with CMN attending a patient conference in Dallas, Texas, in 2012 were invited to participate in the study. Anamnestical data were collected using a standardized questionnaire. Two dermatologists performed clinical examinations. Of 45 patients enrolled, 33 had a giant CMN (G1 [>40 cm PAS], n = 13; G2 [>60 cm PAS], n = 20), 12 had an NCM (5 symptomatic, 7 asymptomatic), and 1 had a history of melanoma. CMN size was positively correlated with NCM (p < 0.05). The classification system allowed an easy and detailed phenotypic characterization of each individual CMN. CMN size and morphology were difficult to assess in patients after surgical removal, and the number of satellite nevi at birth or during infancy was not always known. Our report provides practical aids for the application of the newly proposed CMN classification. Prospective evaluation of accurately classified patients in CMN registries will reveal the predictive value of the scheme. The small study sample limits meaningful conclusions regarding the correlation between CMN parameters and the risk of NCM and melanoma.
Asunto(s)
Nevo Pigmentado , Guías de Práctica Clínica como Asunto , Neoplasias Cutáneas , Adolescente , Adulto , Niño , Femenino , Humanos , Masculino , Adulto Joven , Melanoma/diagnóstico , Melanoma/epidemiología , Melanoma/patología , Melanosis/diagnóstico , Melanosis/epidemiología , Melanosis/patología , Síndromes Neurocutáneos/diagnóstico , Síndromes Neurocutáneos/epidemiología , Síndromes Neurocutáneos/patología , Nevo Pigmentado/clasificación , Nevo Pigmentado/diagnóstico , Nevo Pigmentado/epidemiología , Nevo Pigmentado/patología , Examen Físico , Sistema de Registros , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/patología , Encuestas y CuestionariosRESUMEN
Childhood melanoma (ChM) is rare, with clinical and epidemiologic characteristics that differ from those of adult melanomas. The objective of the current study was to systematically identify and analyze case reports and case series of fatal and metastasizing ChM in the medical literature. ChM case reports with a fatal outcome or metastases were identified using a Medline search and subdivided into ChM developing in the absence of a congenital melanocytic nevus (ChM without CMN) and ChM associated with a CMN (ChM with CMN); 258 cases of ChM without CMN (206 cutaneous, 52 noncutaneous) were identified. In cutaneous ChM without CMN with a fatal outcome (n = 155), the mean age at diagnosis was 13.1 years (median 14 yrs). The mean Breslow index in this group was 8.5 mm for children ages 0 to 10 years and 3.7 mm for children ages 11 to 18 years. In ChM with CMN (n = 178; 112 cutaneous, 66 central nervous system [CNS]), the mean age at diagnosis was 5.8 years for cutaneous melanoma (median 3 yrs) and 5.5 years for CMN-associated CNS melanoma (median 3 yrs). The majority of CMN-associated cutaneous melanomas developed in small and giant CMN (vs medium and large); 53.9% of CNS melanomas developed in patients with multiple medium CMN. This study represents the largest and most complete synopsis of ChM case reports in the medical literature. Our analysis supports the view that cutaneous ChM without CMN (or associated with smaller CMN) differs in several important aspects from ChM associated with large or giant CMN.
Asunto(s)
Melanoma/diagnóstico , Melanoma/secundario , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/etiología , Piel/patología , Adolescente , Factores de Edad , Niño , Preescolar , Progresión de la Enfermedad , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Melanoma/clasificación , Melanoma/patología , Estadificación de Neoplasias , Factores de Riesgo , Neoplasias Cutáneas/patologíaAsunto(s)
GTP Fosfohidrolasas/genética , Genotipo , Proteínas de la Membrana/genética , Nevo Pigmentado/genética , Fenotipo , Análisis de Secuencia de ADN , Neoplasias Cutáneas/genética , Adolescente , Secuencia de Bases , Niño , Preescolar , Femenino , Predisposición Genética a la Enfermedad/genética , Humanos , Lactante , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mutación/genética , Nevo Pigmentado/congénito , Nevo Pigmentado/patología , Piel/patología , Neoplasias Cutáneas/congénito , Neoplasias Cutáneas/patologíaRESUMEN
BACKGROUND: The diameter of congenital melanocytic nevi (CMN) has served as the lone criterion for determining risks of adverse outcomes such as melanoma. A standardized description of additional morphologic features is needed. OBJECTIVE: We sought to develop a consensus-based standardized categorization of cutaneous features of CMN and to test agreement among experts on the proposed scheme. METHODS: An interdisciplinary group of experts in the field of CMN was surveyed using a detailed questionnaire. Applicability of the expert consensus-based scheme was tested for interobserver agreement. RESULTS: The principal variable of the consensus-based categorization is CMN size, based on maximal diameter the CMN is projected to attain by adulthood. CMN size categories include: small (<1.5 cm); medium (M1: 1.5-10 cm, M2: >10-20 cm); large (L1: >20-30 cm, L2: >30-40 cm); and giant (G1: >40-60 cm, G2: >60 cm). In addition, number of satellite nevi in the first year of life is categorized into none, 1 to 20, more than 20 to 50, and more than 50 satellites. Additional descriptors of CMN include anatomic localization, color heterogeneity, surface rugousity and presence of hypertrichosis (described as none, moderate, marked), and presence of dermal or subcutaneous nodules (none, scattered, extensive). Assessment of consistency among 3 experts showed moderate to excellent interobserver agreement for categorization of the clinical descriptors (kappa values 0.54-0.93). LIMITATIONS: Applicability of the proposed scheme was tested in a virtual setting and only among experts. CONCLUSION: The proposed categorization scheme for CMN was agreed upon by experts and showed good interobserver agreement. Such standardized reporting of patients with CMN facilitates the development of an international clinical database for the study of large and giant CMN.
Asunto(s)
Nevo Pigmentado/clasificación , Nevo Pigmentado/congénito , Neoplasias Cutáneas/clasificación , Neoplasias Cutáneas/congénito , Adulto , Humanos , Lactante , Nevo Pigmentado/patología , Variaciones Dependientes del Observador , Pronóstico , Neoplasias Cutáneas/patologíaRESUMEN
Lack of information and misinformation abounds regarding the potential risks of malignancy, management approaches, benefits of surgical intervention, follow-up strategies, and overall prognosis for individuals with congenital melanocytic nevi (CMN). This review is intended to provide answers to questions that frequently arise shortly after the birth of individuals with CMN, especially of larger types.
Asunto(s)
Melanocitos/patología , Melanoma/etiología , Neoplasias Meníngeas/congénito , Nevo Pigmentado/congénito , Neoplasias Cutáneas/congénito , Humanos , Neoplasias Meníngeas/patología , Neoplasias Meníngeas/cirugía , Nevo Pigmentado/patología , Nevo Pigmentado/cirugía , Pronóstico , Riesgo , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/cirugíaAsunto(s)
Internacionalidad , Melanosis/complicaciones , Síndromes Neurocutáneos/complicaciones , Nevo Pigmentado/congénito , Nevo Pigmentado/patología , Neoplasias Cutáneas/congénito , Familia , Alemania , Humanos , Melanosis/patología , Melanosis/psicología , Melanosis/terapia , Síndromes Neurocutáneos/patología , Síndromes Neurocutáneos/psicología , Síndromes Neurocutáneos/terapia , Nevo Pigmentado/psicología , Nevo Pigmentado/terapia , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/patologíaRESUMEN
The term "melanocytic nevus" comprises a group of clinically and pathologically distinct subtypes. In this prospective clinical study we evaluated the frequency, localization, and age and gender distribution of flat nevi (FN), Miescher nevi (MN), and Unna nevi (UN) in a caucasian population. Nevi were counted in 400 patients, of which 47 had a history of melanoma. Additionally, the patients answered to a detailed UV questionnaire. Flat nevi represented the most common type of melanocytic nevi, with a peak in the 3rd decade of life. They were mostly found on the extremities and on the trunk. Miescher nevi were most common in the 6th decade and were predominantly found in the head and neck region. Unna nevi showed a maximum in the 8th decade and they were mainly situated on the trunk. The counts of all three nevus subtypes were elevated in the melanoma group. Our results confirm that FN, MN, and UN represent melanocytic nevi with distinctive morphological and clinical characteristics. The role of sunlight seems to be more prominent in the pathogenesis of FN. The precise description of FN, MN, and UN may serve as a base for a pathogenetic distinction of subtypes of melanocytic nevi in the future.
Asunto(s)
Nevo Pigmentado/clasificación , Neoplasias Cutáneas/clasificación , Adolescente , Adulto , Edad de Inicio , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Neoplasias Faciales/epidemiología , Femenino , Humanos , Queratosis Seborreica/epidemiología , Lentigo/epidemiología , Masculino , Persona de Mediana Edad , Neoplasias Primarias Múltiples/epidemiología , Neoplasias Primarias Múltiples/patología , Nevo Pigmentado/epidemiología , Nevo Pigmentado/patología , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/patología , Luz Solar/efectos adversos , Adulto JovenRESUMEN
Excessive UVR ranks among the most harmful environmental influences on human skin. However, the direct impact of UVR on human skin appendages remains to be systematically investigated. Organ-cultured human anagen hair follicles in vitro were irradiated, and reduction of hair shaft elongation, premature catagen entry, and reduced hair matrix keratinocyte proliferation were observed upon irradiation with UVB (20/50 mJ cm(-2)). At 20 mJ cm(-2), apoptotic cell death prevailed (casp-3/p53 activation), whereas at 50 mJ cm(-2), necrotic cell death was predominant (lactate dehydrogenase increase). Mitochondrial common deletion and oxidatively damaged genomic DNA (8-OH-dG) was mainly observed at 20 mJ cm(-2). Follicular melanogenesis and ACTH immunoreactivity drastically declined, but alpha-melanocyte-stimulating hormone remained unchanged, whereas transforming growth factor-beta(2) expression shifted from the outer toward the inner root sheath. Both the number of Giemsa+ mast cells and the degree of mast-cell degranulation increased in the connective tissue sheath (CTS), and CD117 immunoreactivity of CTS cells and matrix keratinocytes was upregulated. Thus, UVR differentially modifies hair growth and cycle, promotes cell death, and induces complex regulatory events in human hair follicles in vitro. The leads from this human organ model, which is a living and human tissue interaction system under physiologically relevant in situ conditions, may encourage its use for general investigation of UV-induced effects as well as for testing possible agents for their UV-protective potency.
Asunto(s)
Folículo Piloso/patología , Folículo Piloso/efectos de la radiación , Rayos Ultravioleta/efectos adversos , Hormona Adrenocorticotrópica/metabolismo , Apoptosis/efectos de la radiación , Degranulación de la Célula/efectos de la radiación , Diferenciación Celular/efectos de la radiación , División Celular/efectos de la radiación , Fragmentación del ADN/efectos de la radiación , Relación Dosis-Respuesta en la Radiación , Femenino , Cabello/patología , Cabello/efectos de la radiación , Folículo Piloso/metabolismo , Humanos , Queratinocitos/patología , Queratinocitos/efectos de la radiación , Mastocitos/patología , Mastocitos/efectos de la radiación , Melaninas/biosíntesis , Mitocondrias/patología , Mitocondrias/efectos de la radiación , Técnicas de Cultivo de Órganos , Estrés Oxidativo/efectos de la radiación , Factor de Crecimiento Transformador beta2/metabolismo , alfa-MSH/metabolismoRESUMEN
BACKGROUND: Therapeutic angiogenesis has become a key technology in experimental and clinical medicine. Only few data are available on the effects of timing and targeting of therapeutic proteins after cell-based gene transfer. This work investigates such effects after temporary expression of vascular endothelial growth factor 165 (VEGF(165)), the most commonly used angiogenic protein for therapeutic purposes. METHODS: We established a cell-based gene-transfer model using fibroblasts to temporarily produce VEGF(165). Cells were implanted into 40 rats. Protein expression and angiogenic effects were measured by PCR, immunohistology, and microangiography. To determine an improvement for survival of ischemically challenged tissue, cells were implanted in an ischemic flap model at different locations and time points. RESULTS: After implantation of modified cells, a temporary increase was found in the target tissue for VEGF(165), endothelial cell counts, and capillary network formations. Four wk later, histological alterations in the target tissue area were not different from controls. Implantation of modified cells into flap plus wound margin 1 wk before surgery showed significant improvement of tissue survival demonstrated by planimetric measurements and blood vessels counting in the target tissue. CONCLUSION: In our model, temporary expression of VEGF(165) induces therapeutically relevant angiogenesis and improves blood supply only if applied 1 wk before ischemia. It is essential to include the surrounding area for induction of angiogenesis in this model. In contrast, the angiogenic effects are not effective in the target area and its surrounding tissue, if therapeutic gene expression is started during onset of ischemia or 2 wk before ischemia in this model.
Asunto(s)
Fibroblastos/metabolismo , Regulación de la Expresión Génica/fisiología , Terapia Genética/métodos , Isquemia/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo , Adenoviridae , Animales , Proliferación Celular , Endotelio Vascular/citología , Endotelio Vascular/fisiología , Femenino , Fibroblastos/citología , Técnicas de Transferencia de Gen , Isquemia/patología , Modelos Animales , Neovascularización Fisiológica/fisiología , Ratas , Ratas Sprague-Dawley , Colgajos Quirúrgicos/irrigación sanguínea , Factores de Tiempo , Transfección , Factor A de Crecimiento Endotelial Vascular/genéticaRESUMEN
In 2005, an Internet-based network for the support of patients with congenital melanocytic nevi in German-speaking countries was started (http://www.naevus-netzwerk.de). Along with detailed information for patients and parents, the home-page includes a nevus registry which is based on an electronic questionnaire and which aims at providing data on the long-term course of nevi estimated to reach > 10 cm in largest diameter. In the past, congenital melanocytic nevi have been subject to various mythological interpretations ("Tierfellnävus", lit."animal coat nevus";"Muttermal"). Today an increasing body of reliable scientific data allows a differentiated reflection of the risk of malignant transformation and has led to progress in the diagnostic and therapeutic management. Recent findings from the literature and considerations from scientific meetings are reviewed.
Asunto(s)
Redes Comunitarias/organización & administración , Difusión de la Información/métodos , Melanoma/etiología , Nevo Pigmentado/congénito , Nevo Pigmentado/complicaciones , Educación del Paciente como Asunto/métodos , Sistema de Registros , Neoplasias Cutáneas/congénito , Alemania , Humanos , Melanoma/congénito , Educación del Paciente como Asunto/organización & administración , Medición de Riesgo , Neoplasias Cutáneas/etiologíaRESUMEN
Over the last few years, three specific eosinophil activating peptides, eotaxin-1, -2 and -3, members of the chemokine family have been identified. These cytokines exert a number of functions on eosinophils including chemotaxis, transendothelial migration and induction of the release of reactive oxygen species. Eosinophils are considered to play an important role in allergic disease by causing tissue damage through the release of toxic proteases, lipid mediators, cytokines and oxygen free radicals. This article reviews the role of eotaxins in asthma and nasal polyps. Discussion focuses on therapeutic guidelines, particularly as it has been shown that CCR3, the major chemokine receptor in eosinophils, serves as a eotaxin receptor.
Asunto(s)
Asma/etiología , Quimiocinas CC/fisiología , Pólipos Nasales/etiología , Quimiocina CCL11 , Quimiocina CCL24 , Quimiocina CCL26 , HumanosRESUMEN
Durante la última década se han descubierto tres péptidos con actividad quimotáctica específica para los eosinófilos y que son miembros de la familia de las quimocinas. Estas citocinas inducen a los eosinófilos a realizar diferentes funciones como quimotaxis, migración transendotelial e inducción de la liberación de radicales de oxígeno. Como los eosinófilos infiltran tanto las vías aéreas de pacientes asmáticos como los pólipos nasales, se ha postulado que las eotaxinas pueden ser responsables del reclutamiento de estas células. Los eosinófilos tienen la propiedad de inducir remodelamiento de la matriz extracelular y daño tisular a través de la liberación de proteasas tóxicas, mediadores inflamatorios, citocinas y radicales de oxígeno. Por lo cual, el desarrollo de estrategias terapéuticas que inhiban el reclutamiento de estas células constituye una esperanza en el tratamiento de las enfermedades alérgicas. Este artículo revisa la función de las eotaxinas en asma y poliposis nasal, además de discutir el posible uso de antagonistas de CCR3, receptor de las eotaxinas, como una nueva modalidad terapéutica de asma y poliposis nasal.
Over the last few years, three specific eosinophil activating peptides, eotaxin-1, -2 and -3, members of the chemokine family have been identified. These cytokines exert a number of functions on eosinophils including chemotaxis, transendothelial migration and induction of the release of reactive oxygen species. Eosinophils are considered to play an important role in allergic disease by causing tissue damage through the release of toxic proteases, lipid mediators, cytokines and oxygen free radicals. This article reviews the role of eotaxins in asthma and nasal polyps. Discussion focuses on therapeutic guidelines, particularly as it has been shown that CCR3, the major chemokine receptor in eosinophils, serves as a eotaxin receptor.